Chemotherapy With Focal Therapy Can Cure Intraocular Retinoblastoma Without Radiotherapy

Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre

“…In agreement with the studies cited above,20 36 43–45 initial tumour status (ICRB or Reese–Ellsworth groups) was significantly correlated with therapy success. Tumours belonging to ICRB groups A, B and C were easier to cure with CRD than group D and E tumours.…”

“…Relapses/progression occurred, or de novo retinoblastomas developed in 33.9% of this patient cohort, concordant with the relapse rates from studies using other protocols 20. However, our local salvage therapy enabled us to cure >1/3 of the relapsed/progressed eyes without enucleation or EBRT.…”

Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre

“…In agreement with the studies cited above,20 36 43–45 initial tumour status (ICRB or Reese–Ellsworth groups) was significantly correlated with therapy success. Tumours belonging to ICRB groups A, B and C were easier to cure with CRD than group D and E tumours.…”

“…Relapses/progression occurred, or de novo retinoblastomas developed in 33.9% of this patient cohort, concordant with the relapse rates from studies using other protocols 20. However, our local salvage therapy enabled us to cure >1/3 of the relapsed/progressed eyes without enucleation or EBRT.…”

Comparing efficacy and side effects of two systemic chemotherapy regimens for eye‐preserving therapy in children with retinoblastoma

“…A high rate of successful tumor control and eye preservation has been demonstrated after VEC treatment in many retrospective studies worldwide 8–10,23,24 . The reported treatment failure‐free eye survival in these studies is in line with the 2‐year EFES of 72.3% after VEC treatment presented here, while the number of therapy failures was significantly higher (2‐year EFES 50.4%) after CyVEC treatment.…”

“…A high rate of successful tumor control and eye preservation has been demonstrated after VEC treatment in many retrospective studies worldwide. [8][9][10]23,24 The reported treatment failure-free eye survival in these studies is in line with the 2-year EFES of 72.3% after VEC treatment presented here, while the number of therapy failures was significantly higher (2-year EFES 50.4%) after CyVEC treatment. The CyVEC regimen contains additional cyclophosphamide and less carboplatin than the VEC regimen, while the cumulative doses of vincristine and etoposide are equal in both regimens.…”

Clinicopathologic review of pediatric enucleations during the last 50 years

“…The management of bilateral RB has improved substantially during the last 50 years, with earlier diagnosis and the use of globe-preserving treatment methods, such as plaque brachytherapy, stereotactic and proton beam radiotherapy, cryotherapy, chemoreduction, and chemothermotherapy. [25][26][27][28] Gender/Age In agreement with previous studies, our study found a predominance of male compared to female subjects undergoing pediatric enucleation. 9,17,[28][29][30] For trauma, the male predominance was considerable at 81.1%, similar to that reported by others.…”

Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre

“…In agreement with the studies cited above,20 36 43–45 initial tumour status (ICRB or Reese–Ellsworth groups) was significantly correlated with therapy success. Tumours belonging to ICRB groups A, B and C were easier to cure with CRD than group D and E tumours.…”

“…Relapses/progression occurred, or de novo retinoblastomas developed in 33.9% of this patient cohort, concordant with the relapse rates from studies using other protocols 20. However, our local salvage therapy enabled us to cure >1/3 of the relapsed/progressed eyes without enucleation or EBRT.…”

Comparing efficacy and side effects of two systemic chemotherapy regimens for eye‐preserving therapy in children with retinoblastoma

“…A high rate of successful tumor control and eye preservation has been demonstrated after VEC treatment in many retrospective studies worldwide 8–10,23,24 . The reported treatment failure‐free eye survival in these studies is in line with the 2‐year EFES of 72.3% after VEC treatment presented here, while the number of therapy failures was significantly higher (2‐year EFES 50.4%) after CyVEC treatment.…”

“…A high rate of successful tumor control and eye preservation has been demonstrated after VEC treatment in many retrospective studies worldwide. [8][9][10]23,24 The reported treatment failure-free eye survival in these studies is in line with the 2-year EFES of 72.3% after VEC treatment presented here, while the number of therapy failures was significantly higher (2-year EFES 50.4%) after CyVEC treatment. The CyVEC regimen contains additional cyclophosphamide and less carboplatin than the VEC regimen, while the cumulative doses of vincristine and etoposide are equal in both regimens.…”

Clinicopathologic review of pediatric enucleations during the last 50 years

“…The management of bilateral RB has improved substantially during the last 50 years, with earlier diagnosis and the use of globe-preserving treatment methods, such as plaque brachytherapy, stereotactic and proton beam radiotherapy, cryotherapy, chemoreduction, and chemothermotherapy. [25][26][27][28] Gender/Age In agreement with previous studies, our study found a predominance of male compared to female subjects undergoing pediatric enucleation. 9,17,[28][29][30] For trauma, the male predominance was considerable at 81.1%, similar to that reported by others.…”

Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre

“…In agreement with the studies cited above,20 36 43–45 initial tumour status (ICRB or Reese–Ellsworth groups) was significantly correlated with therapy success. Tumours belonging to ICRB groups A, B and C were easier to cure with CRD than group D and E tumours.…”

“…Relapses/progression occurred, or de novo retinoblastomas developed in 33.9% of this patient cohort, concordant with the relapse rates from studies using other protocols 20. However, our local salvage therapy enabled us to cure >1/3 of the relapsed/progressed eyes without enucleation or EBRT.…”

Comparing efficacy and side effects of two systemic chemotherapy regimens for eye‐preserving therapy in children with retinoblastoma

“…A high rate of successful tumor control and eye preservation has been demonstrated after VEC treatment in many retrospective studies worldwide 8–10,23,24 . The reported treatment failure‐free eye survival in these studies is in line with the 2‐year EFES of 72.3% after VEC treatment presented here, while the number of therapy failures was significantly higher (2‐year EFES 50.4%) after CyVEC treatment.…”

“…A high rate of successful tumor control and eye preservation has been demonstrated after VEC treatment in many retrospective studies worldwide. [8][9][10]23,24 The reported treatment failure-free eye survival in these studies is in line with the 2-year EFES of 72.3% after VEC treatment presented here, while the number of therapy failures was significantly higher (2-year EFES 50.4%) after CyVEC treatment. The CyVEC regimen contains additional cyclophosphamide and less carboplatin than the VEC regimen, while the cumulative doses of vincristine and etoposide are equal in both regimens.…”

Clinicopathologic review of pediatric enucleations during the last 50 years

“…The management of bilateral RB has improved substantially during the last 50 years, with earlier diagnosis and the use of globe-preserving treatment methods, such as plaque brachytherapy, stereotactic and proton beam radiotherapy, cryotherapy, chemoreduction, and chemothermotherapy. [25][26][27][28] Gender/Age In agreement with previous studies, our study found a predominance of male compared to female subjects undergoing pediatric enucleation. 9,17,[28][29][30] For trauma, the male predominance was considerable at 81.1%, similar to that reported by others.…”